Lantern Pharma Inc. · NASDAQ:LTRN
Lantern Pharma — IPO Roadshow (January 2021)
44 slides from Lantern Pharma's IPO roadshow presentation, Jan 11, 2021
Slide 1: Lantern Pharma Company Overview
Nasdaq: LTRN 1 Lantern Pharma Company Overview January 11, 2021 Leveraging A.I., Machine Learning & Genomics to Rescue, Repurpose and Develop Targeted Cancer Therapies Filed Pursuant to Rule 433 Registration Statement No. 333 - 251992 Issuer Free Writing Prospectus dated January 11, 2021 Relating to
Slide 2: Special Note Regarding Forward-Looking Statements
Nasdaq: LTRN 2 SPECIAL NOTE REGARDING FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended . These forward - looking sta
Slide 3: Free Writing Prospectus
Nasdaq: LTRN 3 FREE WRITING PROSPECTUS • We have filed a registration statement (including a prospectus) with the SEC for the offering to which this communication rel ate s. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with
Slide 4: Rescuing failed or abandoned cancer drugs with RADR
Nasdaq: LTRN 4 Drugs that have failed clinical trials or have been abandoned by pharma and biotech companies in late stage trials • Big data (genomic, clinical, response) assembled and analyzed • Patient subgroups identified through machine learning and artificial intelligence • Mechanisms of action
Slide 5: Current oncology drug development is costly, risky, and inefficient
Nasdaq: LTRN 5 Current oncology drug development is costly, risky, and inefficient … a perfect problem area for artificial intelligence & machine learning 3.3% (1) Avg. success rate of oncology drugs $2.8B (2) R&D investment to bring new cancer drug to market 2009 - 2018 17,000+ Oncology trials cond
Slide 6: Critical need to rescue failed drugs and improve ROI
Nasdaq: LTRN 6 1. “... low efficacies of cancer drugs might be attributed to the heterogeneity of the tested patient population , which essentially dilutes the strong therapeutic effect that a drug might have on a specific patient subgroup .” Thiebault Geoux , Ph.D. Chemistry - Elsevier 11/9/2015 10
Slide 7: Scalable, Unique Artificial Intelligence Platform – RADR
Nasdaq: LTRN 7 Scalable, Unique Artificial Intelligence Platform – RADR® • 1+ Billion datapoints covering over 140+ drug/tumor interactions • Validated in multiple case studies with over 80%+ blinded accuracy • Integration of real - world, patient data from thousands of patients • Active collaborati
Slide 8: Major pillars of shareholder and patient value
Nasdaq: LTRN 8 x Has identified several indications for new, genomically validated programs for LP - 184 x Provided insights and targets for pursuit using an ADC approach x Scaled 4x+ since IPO, plan an increase of 3x to 5x during 2021 calendar year x Potential to significantly reduce the complexity
Slide 9: Datapoints powering RADR
Nasdaq: LTRN 9 Types of data: • Complete transcriptome data • RNA gene expression data • Drug sensitivity data • DNA copy number and mutation data • Clinical stage of tumor /cancer • Histology of tumor • Patient age , sex , race and ethnicity • Prior treatment history and response * Historical datap
Slide 10: Lantern's Unique & Rapidly Developing Pipeline
Nasdaq: LTRN 10 Lantern’s Unique & Rapidly Developing Pipeline Accelerated Development by Leveraging the RADR ® A.I. platform 80+ issued patents and pending applications across 14 patent families Phase I Phase II LP - 184 LP - 100 (Irofulven) LP - 300 Drug Preclinical Indication Prostate Cancer Succ
Slide 11: Patient populations and potential oncology therapy sales
Nasdaq: LTRN 11 Nearly 1 M patients annually worldwide with several Billion $USD in potential future oncology therapy sales Prostate Cancer Non - Small Cell Lung Cancer (NSCLC) Ovarian, Pancreatic & Liver Cancer 1.3 million 2018 Estimated Global Incidence 208,000 2018 Estimated G lobal metastatic ho
Slide 12: Overview of Lantern's Small Molecule Portfolio
Nasdaq: LTRN 12 Overview of Lantern’s Small Molecule Portfolio LP - 100, Irofulven LP - 184 LP - 300 • DNA Damaging Agent • Mediates cytotoxicity through multiple mechanisms such as DNA adduct formation, RNA polymerase stalling and redox protein modification • Use in a precision medicine, genomic -
Slide 13: LP-100 (Irofulven): Historical phase II trial results in prostate cancer
Nasdaq: LTRN 13 LP - 100 ( Irofulven ): Historical* phase II trial results in prostate cancer *Historical data from Hart et al., Randomized phase II trial of irofulven /prednisone, irofulven /capecitabine/prednisone, or mitoxantrone/prednisone in hormone refractory prostate cancer (HRPC) patients fa
Slide 14: LP-300 in development for never-smokers with NSCLC adenocarcinoma
Nasdaq: LTRN 14 LP - 300 in development for never - smokers with NSCLC adenocarcinoma based on strong historical data & biomarker studies Mechanism of action • Disulfide bond disrupting agent • Disrupts by covalently modifying cysteine • Inhibits and modulates activity of proteins in NSCLC pathways
Slide 15: LP-300 prior Phase III 2-year survival by subgroup
Nasdaq: LTRN 15 Source: Phase 3 clinical trial, study ID DMS32212R, conducted by BioNumerik Pharmaceuticals - subpopulations receiving paclitaxel/cisplatin 30% 51% 63% 72% 25% 31% 28% 32% All patients Females never-Smokers Female never-Smokers 2 Year Survival % LP-300 + Cisplatin/ Paclitaxel Placebo
Slide 16: LP-300 survival curves in Phase III subgroups
Nasdaq: LTRN 16 All never - smokers N = 87, HR = 0.519 (p value 0.0462) Survival months Survival probability 0 10 20 30 1.0 0.8 0.6 0.4 0.2 0.0 LP - 300 + Cisplatin/Paclitaxel Placebo + Cisplatin/Paclitaxel All females N = 114, HR = 0.579 (p value 0.0477) LP - 300 + Cisplatin/Paclitaxel Placebo + Ci
Slide 17: Proposed design for relaunching Phase II trial for LP-300
Nasdaq: LTRN 17 Proposed design for relaunching of Phase II clinical trial for LP - 300 in a targeted patient population Histology / demographic/ smoking history screening LP - 300 + standard of care (Dosing every 3 weeks and up to 8 treatment cycles) Efficacy Endpoints Never - smoker NSCLC Adenocar
Slide 18: Lung Cancer in Never-Smokers – a hidden but rising disease
Nasdaq: LTRN 18 Lung Cancer in Never - Smokers (LCINS) – a hidden but rising disease • 7 th leading cause of death among patients with solid tumors • More frequent in women with ~2/3 of patients with no reported smoking history • Adenocarcinoma is the most common histology accounting for ~60% of non
Slide 19: LP-184 for solid tumors and ADC program
Nasdaq: LTRN 19 LP - 184 for solid tumors and certain PTGR1 expressing cancers & ADC program Unique Features • Hydroxyurea Methylacylfulvene • Nanomolar potency across multiple solid tumor (pancreas, prostate, liver) and glioblastoma cell lines • Broad anti - tumor agent that counteracts multi - dru
Slide 20: LP-184 tumor regression in mouse model
Nasdaq: LTRN 20 LP - 184 treatment resulted in greater tumor regression in a mouse model with human cancer Source: Staake et al., Bioorganic & Medicinal Chemistry Letters (2016) 10 1 0.1 10 20 30 Time (days) Relative Tumor Weight No Drug LP - 100, 10 mg/kg LP - 184, 10 mg/kg LP - 184, 20 mg/kg Drugs
Slide 21: Proposed LP-184 mechanism of action
Nasdaq: LTRN 21 Proposed LP - 184 mechanism of action based on acylfulvene drugs 1. Potential synergistic drug combinations due to involvement w/ DNA repair pathway and supported by gene correlation studies 2. Approved drugs in certain drug classes have been identified to be synergistic with LP - 18
Slide 22: Tumors with highest potential based on PTGR1 expression
Nasdaq: LTRN 22 Tumors with highest potential based on PTGR1 expression and gene signature activity Lung Prostate Kidney Colon Brain / CNS LP - 184: High Positive Pan Tumor Correlation with PTGR1 Expression 40 kDa sgRNA#1 #2 #3 sgCrtl Parental P ANC03.27+ dCas9-KRAB A 0 25 50 75 100 125 #1 #2 #3 C t
Slide 23: LP-184 in vitro potency versus approved chemotherapeutics
Nasdaq: LTRN 23 1 10 100 1,000 10,000 100,000 1,000,000 SNU387_Liver H2228_NSCLC H1944_NSCLC OV90_Ovary NIHOVCAR3_Ovary IC50 [ nM ] Cell Line ID_Cancer Type LP-184 Cisplatin Pemetrexed Nanomolar potency Micromolar potency LP - 184 shows a 10x – 3,800x increase in in vitro potency over approved chemo
Slide 24: LP-184 in Glioblastoma
Nasdaq: LTRN 24 LP - 184 shows significant promise in improving patient outcomes in Glioblastoma (GBM) – a rare cancer with median survival of < 1 year 37.4 46.4 47.7 231 274000 513000 293000 129000 1 10 100 1,000 10,000 100,000 1,000,000 SF268 SF295 SNB75 U251 IC50 [ nM ] Comparative sensitivity of
Slide 25: LP-184 in ex vivo PDX models of DNA damage repair deficient tumors
Nasdaq: LTRN 25 LP - 184 is highly effective in ex vivo PDX models of DNA Damage Repair Deficient (HRD+) solid tumors LP - 184 response in a representative pancreatic cancer model with PARP1, ATR* and BRIP1 mutations Patient was a non - responder to 5 - Fluorouracil/ Irinotecan/ Oxaliplatin combinat
Slide 26: LP-184 IC50 values in ATRT cell lines
Nasdaq: LTRN 26 LP - 184 IC50 values in multiple ATRT cell lines suggest that it is able to potently kill these cancers LP - 184 shows in vitro potency in ATRT - an ultra - rare CNS cancer mostly occurring in children driven by SMARCB1 expression as predicted by RADR 1770 162 37.4 1 10 100 1000 CHLA
Slide 27: Initial data from ADC Program
Nasdaq: LTRN 27 Initial data from ADC Program Converted an antibody with no intrinsic biological activity to an ADC! One can treat even MDR refractory leukemias (whether T - cell, B - cell, myeloid or myeloma leukemias) LP - A18 has an LD50 of 7 nM versus IC50 2 - 7 nM for Adcetris ® or Kadcyla ® LP
Slide 28: RADR – robust and scalable platform
Nasdaq: LTRN 28 RADR ® - A robust and scalable platform for accelerating the development of targeted cancer therapy, precision trials and Companion Dx Model Data Sets Data Sources AI Methods Being Deployed • > 1 Billion transcriptomic and drug sensitivity data points • >144 drug - tumor interactions
Slide 29: RADR identifies genetic markers and signatures
Nasdaq: LTRN 29 RADR ® identifies genetic markers and signatures for precision oncology drug development, clinical response prediction and CDx enablement Output & Signature Development Process Platform Architecture Success in Blinded Predictions Oncology Patient Records & Response Information Drug -
Slide 30: RADR Workflow Details
Nasdaq: LTRN 30 Uses machine learning methods to train on datasets Parameter tuning and model development and evaluation Biomarker Pa nel or Gene Signature for a CDx Guidance for clinical trial design & studies Training Set Optimal model used on testing dataset Genetic D ata Drug S ensitivity Data G
Slide 31: Our Intellectual Property Portfolio
Nasdaq: LTRN 31 108 Issued Patents Our Intellectual Property Portfolio – Extensive and continually growing position of over 80 issued patents & patent applications across 14 patent families Methods of Use Composition of Matter Drug Sensitivity & Response Signatures using Biomarkers LP - 100 LP - 184
Slide 32: Studies & Collaborations With Top Tier Academic & Research Partners
Nasdaq: LTRN 32 Studies & Collaborations With Top Tier Academic & Research Partners
Slide 33: Heavy investment & investor interest in A.I. driven drug development
Nasdaq: LTRN 33 Heavy investment & investor interest in A.I. driven drug development Company Investment Feb. 2020 IPO (NASDAQ: SDGR) $239+ M. total Latest 09/2020 Series D Mar. 2018 IPO (NASDAQ: BTAI) $123+ M. total Latest 08/2020 Series B Valuation* $6,100+ Million $232 M. raised at IPO $1,300+ Mil
Slide 34: Value Building Milestones & Inflection Points
Nasdaq: LTRN 34 Value Building Milestones & Inflection Points 2021 2022 x LP - 300 Phase 2 Clinical Trial Launch x Advancement of CNS Programs w/ LP - 184 (GBM & ATRT) x Data from key collaborations Fox Chase, Georgetown and Johns Hopkins x Finalize IND - Enabling studies for LP - 184 in select geno
Slide 35: Cap Table
Nasdaq: LTRN 35 Cap Table LANTERN PHARMA INC. (LTRN) Common Shares Outstanding 6,217,577 Warrants (WAEP $3.13) Underwriter Warrants (Exercise Price at $18.75) 262,014 70,000 Options (Employees, Management and Directors) 820,608 Fully Diluted Shares Outstanding 7,370,199 • Management and Directors ow
Slide 36: Management Team
Nasdaq: LTRN 36 Highly experienced in innovation for pharma, drug development & oncology Management Team Kishor Bhatia, Ph.D., FRC Path Chief Scientific Officer A highly skilled scientist, inventor, manager, and administrator with over thirty years of experience building research programs and teams
Slide 37: Investment Highlights
Nasdaq: LTRN 37 Investment Highlights - Lantern Pharma has a unique, growing and validated foundation for the future of cancer therapy and patient care Focused on cancer drug market segments with clear clinical need , understood mechanisms, targeted patient populations that exceed 1 Million , and mu
Slide 38: Thank you!
Nasdaq: LTRN 38 Lantern Pharma Company Overview Thank you! January 11, 2021
Slide 39: Appendix Items
Nasdaq: LTRN 39 Appendix Items • Global A.I. Healthcare and Drug Discovery Market • Mega Trends Shaping the Future of Cancer Therapy • Source of Irofulven , LP - 100 • Board of Directors – Biographical sketches • Select recent publications and posters
Slide 40: A.I. driven drug discovery is a rapidly growing market
Nasdaq: LTRN 40 Drug discovery and development driven by A.I. is a rapidly growing market in response to fundamental shifts in the industry and a re - tooling of R&D 0 200 400 600 800 1000 1200 2016 2024 *Source: Biopharmatrend.com , PMLiVE, and Global Market Insights, Inc. ~$4B A.I. - driven Drug D
Slide 41: Mega Trends Shaping Drug Development
Nasdaq: LTRN 41 Solving unmet needs and creating opportunities in personalizing cancer therapy by capitalizing on emerging technologies and industry trends 1. Increased access to validated genomic & biomarker data 2. Increased sharing and collaboration globally among research groups, industry consor
Slide 42: Irofulven, LP-100, is derived from the Jack O'Lantern mushroom
Nasdaq: LTRN 42 Irofulven , LP - 100, is derived from the Jack O’Lantern mushroom LP - 100, Irofulven LP - 184 LP - 300 • DNA Damaging Agent • Derived from highly toxic substance found in Jack o’Lantern mushroom – Illudin S • Company name “Lantern” is also derived from this origin of the compound •
Slide 43: Board of Directors
Nasdaq: LTRN 43 Jeff Donald Keyser, Ph.D., J.D., MPA • Board Chairman • Founder of Renibus Therapeutics and ZSPharma Franklyn Prendergast, M.D., Ph.D. Emeritus • Board of Governors and Board of Trustees, Mayo Clinic • Professor and Director – Mayo Clinic Comprehensive Cancer Center • Emeritus Member
Slide 44: Select Other Publications & Posters
Nasdaq: LTRN 44 Select Other Publications & Posters https:// ascopubs.org / doi /abs/10.1200/JCO.2020.38.15_suppl.e21660 https:// cancerres.aacrjournals.org /content/79/13_Supplement/4789 https:// www.lanternpharma.com /wp - content/uploads/2020/06/AACR - 2020 - LP - NCI - poster - final - pdf - 1.p